Use of IL-17 inhibitors is effective and safe for the treatment of PsO involving difficult-to-treat anatomical sites.

Tildrakizumab delivers sustained improvements in psoriasis severity and patient-reported outcomes, according to a recent Italian study.

Behavioral, pharmacological, and surgical weight loss interventions among adults with psoriasis is associated with significant improvements in Psoriasis Area and Severity Index scores compared with ...